一、基本信息
姓名：鲁冰
职称：教授，博士生导师
联系邮箱：Lubing_grace@163.com
二、学习经历
2014.9-2019.7 中山大学，中山医学院，博士
2009.9-2014.7 青岛大学，医学院，学士
三、承担教学任务
四、主要研究方向
主要从事肿瘤恶性进展中表观遗传调控的机制研究，鉴定肿瘤分子标志物或治疗靶标，为实现肿瘤精准诊疗提供科学依据。主要包括：
（1） 利用表观多组学技术系统解析异常修饰调控肿瘤染色质状态驱动肿瘤发生发展的机理；
（2）结合高通量染色体构象捕获技术探究生物大分子凝聚体重塑肿瘤三维基因组机制，解析肿瘤三维基因组重塑对基因转录调控作用；
（3）在上述基础上，开发靶向治疗新策略。
五、主要学术任职
六、培养学生情况
七、主要获奖情况
八、代表性论文
[1] Lu, B. #., Qiu, R. #., Wei, J. #., Wang, L. #., Zhang, Q., Li, M., Zhan, X., Chen, J., Hsieh, I.Y., Yang, C., et al. (2024). Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer. Nat Cancer.5, 1622-1640. (IF=23.5)
[2] Lu B#., Zou C#., Yang M., He Y., He J., Zhang C., Chen S., Yu J., Liu K. Y., Cao Q., Zhao W*. (2021) Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Advanced science. e2101895. (IF=16.806)
[3] Lu, B., Wei, J., Zhou, H., Chen, J., Li, Y., Ye, L., Zhao, W., and Wu, S. (2022). Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3. Cell Death Dis 13, 547. 1 (IF=9.685)
[4] Lu B#., Huang X#., Mo J., Zhao W*. (2016) Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Frontiers in pharmacology 7:84. (IF= 5.814)
[5] Lu B#., He Y#., He J., Wang L., Liu Z., Yang J., Gao Z., Lu G., Zou C*., Zhao W*. (2020) Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma. Molecular cancer research .18(1):57. (IF=5.852)
[6] Lin B#., Lu B#., Hsieh I. y., Liang Z., Sun Z., Yi Y., Lv W*., Zhao W*., Li J*. (2020) Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer. Frontiers in Pharmacology 11:632. (IF= 5.814)
[7] Yi Y#., Li Y#., Meng Q#., Li Q., Li F., Lu B., Shen J., Fazli L., Zhao D., Li C., Jiang W., Wang R., Liu Q., Szczepanski A., Li Q., Qin W., Weiner A. B., Lotan T. L., Ji Z., Kalantry S., Wang L., Schaeffer E. M., Niu H., Dong X., Zhao W., Chen K*., Cao Q*. (2021) A PRC2-independent function for EZH2 in regulating rRNA 2'-O methylation and IRES-dependent translation. Nature cell biology 23(4):341. (IF= 28.824)
[8] Guo, W. #., Wang, X. #., Lu, B. , Yu, J., Xu, M., Huang, R., Cheng, M., Yang, M., Zhao, W., and Zou, C. (2023). Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma. Cell Death Dis 14, 439. (IF= 9)
[9] Wang L#., Huang X#., You X#., Yi T., Lu B., Liu J., Lu G., Ma M., Zou C., Wu J*., Zhao W*. (2020) Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma. Signal transduction and targeted therapy 5(1):196. (IF= 18.183)
[10] Mo J., Wang L., Huang X., Lu B., Zou C., Wei L., Chu J., Eggers P. K., Chen S., Raston C. L., Wu J*., Lim L. Y*., Zhao W*. (2017) Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis. Nanoscale 9(35):13142. (IF=7.790)
[11] Hsieh I. Y., He J., Wang L., Lin B., Liang Z., Lu B., Chen W., Lu G., Li F., Lv W., Zhao W*., Li J*. (2020) H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis. Biomedicine & pharmacotherapy 123:109728. (IF= 6.529)
本课题组长期招收具有生物信息学、基因组学、分子生物学、细胞生物学等相关专业背景的硕士生、博士生、博士后和特聘研究人员，欢迎对肿瘤表观遗传调控研究感兴趣的同学加入我们团队！
